|Day Low/High||111.47 / 113.10|
|52 Wk Low/High||62.55 / 113.41|
Today there was a virtual vacuum of good news in the stock market.
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
Shares of AbbVie were lower Friday after posting disappointing third-quarter revenue.
McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.
With Clinton apparently headed for victory, worries about her being a threat to health-care stocks have peaked.
If and when interest rates go up, this basket of stocks should continue to do well.
Small biotech tanked on weak earnings, but still seems promising.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Stocks secure robust gains after the latest labor market snapshot breezes past expectations.
Rarely do investors get to buy these types of quality businesses at such discounted prices.
The sector seems to be rebounding after tumbling by more than 40%.
The bifurcation can be seen just by looking at Apple's recent results.
Shares of AbbVie were up Friday after the company reported a big jump in revenue.
Consider raising your sell stop protection to a close below $61.
The Anheuser-Busch InBev and SABMiller deal is another step closer to completion.
It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.
Valuations are stretched in certain names and industries, so some profit-taking appears in order.
These names are now oversold and are sitting at attractive prices.
Analysts cut valuation estimates after a disappointing drug study.
With the recent pullback in the stock price, AbbVie is an attractive buy.
Social media chatter on Wall Street ranged from new forms of so-called 'thematic ETFs' to spiking volatility.
Further near-term weakness to $60 looks like a good spot to go long. Use an appropriate risk level.